L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:964998 CAPLUS Full-text
DN 141:410970
TI Preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions
IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V., III; Marugan Sanchez, Juan Jose; Gushue, Joan; Leonard, Kristi
PA 3-Dimensional Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004096134	A2	20041111	WO 2004-US12240	20040421

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-465265P P 20030425
OS MARPAT 141:410970
GI



I



II

AB The title compds. [I; R = halo, alkyl, CN, cycloalkyl, etc.; n = 0-2; X X = a bivalent radical such as alkanediyl, etc.; R3 = CO2R0, CO2M (wherein R0 = H, alkyl, cycloalkyl; M = cation); R5 = cycloalkyl, aryl, heteroaryl, etc.; R6 = cycloalkyl, aryl, heteroaryl, etc.; R7 = H, alkyl, cycloalkyl, (cycloalkyl)alkyl; R8 = H, alkyl], useful as inhibitors of HDM2-p53 interactions for treating cancer, inflammatory condition or autoimmune disease, were prepared and formulated. E.g., a multi-step synthesis of II, which showed IC50 of 0.1-1.0 μM against binding of p53 to MDM2, was given.
IT **787632-90-0P 787632-91-1P 787632-92-2P**
787632-93-3P 787632-94-4P 787632-95-5P
787632-96-6P 787632-97-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)
RN 787632-90-0 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 2-amino-3-(4-chlorophenyl)-4-[(1R)-1-(4-

chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-91-1 CAPLUS
CN Acetamide, 2-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-92-2 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(2-hydroxyethyl)amino]-7-iodo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-93-3 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(3-hydroxypropyl)amino]-7-iodo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-94-4 CAPLUS
CN Acetamide, N-[2-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-95-5 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-2-(methylamino)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-96-6 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 2-[(2-aminoethyl)amino]-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-97-7 CAPLUS
CN Propanamide, 3-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Me
R
O
I
N
S
Cl
H
N
N
Cl
O
NH2

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:934324 CAPLUS Full-text
DN 141:395589
TI Preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease.
IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V.; Marugan, Sanchez Juan Jose; Gushue, Joan; Leonard, Kristi
PA USA
SO U.S. Pat. Appl. Publ., 58 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004220179	A1	20041104	US 2004-829040	20040421
	US 2005227932	A1	20051013	US 2005-72391	20050304
PRAI	US 2003-465264P	P	20030425		
	US 2002-292876	A2	20021113		
	US 2004-829040	A1	20040421		

OS MARPAT 141:395589
GI



I

AB Title compds. e.g. [I; Ra = halo, alkyl, alkenyl, alkynyl, cyano, cycloalkyl, OH, alkoxy, CO2H, alkoxycarbonyl, acyl, carbamoyl, (alkyl)aminocarbonyl, alkylthio, amino, NO2; X = alkylene, cycloalkylene, (substituted) arylene, heteroarylene, arylalkylene, heteroarylalkylene; R3 = CO2Rd, CO2M; Rd = H, alkyl, (substituted) cycloalkyl; M = cation; R5, R6 = (substituted) cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, (unsatd.) heterocyclyl; R7 = H, alkyl, cycloalkyl, cycloalkylalkyl; R8 = H, alkyl; n = 0-2], were prepared Thus, 4-[(R)-1-(2-amino-4-chlorophenyl)ethyl]-(3S)-3-(4-chlorophenyl)-7-iodo-1- [2-(2-methoxyethoxy)ethyl]-1,4-benzodiazepine-2,5-dione inhibited MDM2 binding to a p53 peptide analog with IC50 = 0.1-1.0 μM.
IT **787632-90-0P 787632-91-1P 787632-92-2P**
787632-93-3P 787632-94-4P 787632-95-5P
787632-96-6P 787632-97-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)
RN 787632-90-0 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 2-amino-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-91-1 CAPLUS
CN Acetamide, 2-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-92-2 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(2-hydroxyethyl)amino]-7-iodo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-93-3 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-2-[(3-hydroxypropyl)amino]-7-iodo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-94-4 CAPLUS
CN Acetamide, N-[2-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-95-5 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-2-(methylamino)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-96-6 CAPLUS
CN 5H-1,4-Benzodiazepin-5-one, 2-[(2-aminoethyl)amino]-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-97-7 CAPLUS
CN Propanamide, 3-[[3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-4,5-dihydro-7-iodo-5-oxo-3H-1,4-benzodiazepin-2-yl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Me
R
O
N
I
S
Cl
N
H
N
Cl
O
NH2

```
=> d l2; d his; log y
L2 HAS NO ANSWERS
L1              STR
```




```
G1 Cb,Hy,Ak
Structure attributes must be viewed using STN Express query preparation.
L2              QUE  ABB=ON  PLU=ON  L1

     (FILE 'HOME' ENTERED AT 16:26:06 ON 30 NOV 2005)

     FILE 'REGISTRY' ENTERED AT 16:26:14 ON 30 NOV 2005
L1              STRUCTURE UPLOADED
L2              QUE L1

     FILE 'STNGUIDE' ENTERED AT 16:27:21 ON 30 NOV 2005

     FILE 'REGISTRY' ENTERED AT 16:28:46 ON 30 NOV 2005
L3            0 S L2
L4            8 S L2 FUL

     FILE 'CAPLUS' ENTERED AT 16:29:11 ON 30 NOV 2005
L5            2 S L4

     FILE 'BEILSTEIN' ENTERED AT 16:29:38 ON 30 NOV 2005
L6            0 S L2
L7            0 S L2 FUL

     FILE 'MARPAT' ENTERED AT 16:30:01 ON 30 NOV 2005
L8            0 S L2
L9            2 S L2 FUL
L10           0 S L9 NOT L5

COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           113.53     286.44

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)  SINCE FILE      TOTAL
                                              ENTRY    SESSION
CA SUBSCRIBER PRICE                             0.00      -1.46

STN INTERNATIONAL LOGOFF AT 16:30:32 ON 30 NOV 2005
```

1-26

L5 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:964998 CAPLUS Full-text
DN 141:410970
TI Preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions
IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V., III; Marugan Sanchez, Juan Jose; Gushue, Joan; Leonard, Kristi
PA 3-Dimensional Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 166 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004096134	A2	20041111	WO 2004-US12240	20040421

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2003-465265P P 20030425
OS MARPAT 141:410970
GI



I



II

AB The title compds. [I; R = halo, alkyl, CN, cycloalkyl, etc.; n = 0-2; X X = a bivalent radical such as alkanediyl, etc.; R3 = CO2R0, CO2M (wherein R0 = H, alkyl, cycloalkyl; M = cation); R5 = cycloalkyl, aryl, heteroaryl, etc.; R6 = cycloalkyl, aryl, heteroaryl, etc.; R7 = H, alkyl, cycloalkyl, (cycloalkyl)alkyl; R8 = H, alkyl], useful as inhibitors of HDM2-p53 interactions for treating cancer, inflammatory condition or autoimmune disease, were prepared and formulated. E.g., a multi-step synthesis of II, which showed IC50 of 0.1-1.0 μM against binding of p53 to MDM2, was given.

IT **787632-98-8P 787632-99-9P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)

RN 787632-98-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-

chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methoxycarbonyl)-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-99-9 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-carboxy-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, α-(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **528849-68-5P 787632-60-4P 787632-61-5P**
787632-62-6P 787632-64-8P 787632-65-9P
787632-66-0P 787632-67-1P 787632-68-2P
787632-69-3P 787632-70-6P 787632-71-7P
787632-72-8P 787632-73-9P 787632-74-0P
787632-75-1P 787632-76-2P 787632-77-3P
787632-78-4P 787632-79-5P 787632-80-8P
787632-81-9P 787632-82-0P 787632-83-1P
787632-84-2P 787632-85-3P 787632-86-4P
787632-87-5P 787632-88-6P 787632-89-7P
787633-00-5P 787633-01-6P 787633-02-7P
787633-03-8P 787633-04-9P 787633-05-0P
787633-06-1P 787633-07-2P 787633-08-3P
787633-09-4P 787633-10-7P 787633-11-8P
787633-15-2P 787633-16-3P 787633-17-4P
787633-20-9P 787633-21-0P 787633-23-2P
787633-24-3P 787633-25-4P 787633-26-5P
787633-27-6P 787633-28-7P 787633-29-8P
787633-30-1P 787633-33-4P 787633-34-5P
787633-35-6P 787633-36-7P 787633-37-8P
787633-38-9P 787633-40-3P 787633-43-6P
787633-44-7P 787633-45-8P 787633-48-1P
787633-49-2P 787633-50-5P 787633-51-6P
787633-52-7P 787633-53-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)

RN 528849-68-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-60-4 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787632-61-5 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 787632-62-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 787632-64-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-65-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-66-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-67-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-68-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-69-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-70-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethoxy)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-71-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-hexanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-72-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-heptanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-73-9 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-74-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-butanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-75-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-propanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-76-2 CAPLUS
CN 2-Furancarboxylic acid, 5-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-77-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 8-chloro-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-78-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)cyclopropylmethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-79-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(3,4-dichlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-80-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(3-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-81-9 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-3-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-82-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-4-[1-(4-methyl-1-naphthalenyl)ethyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-83-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-84-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[2-(4-chlorophenyl)-1-methylethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-85-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-bromophenyl)-4-{(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-86-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-acetic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 787632-87-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-3-nitrophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-88-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-89-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-amino-4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-00-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-(aminocarbonyl)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-01-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787633-02-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-03-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-04-9 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-05-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-06-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-07-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-08-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-09-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-[(trifluoromethyl)thio]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-10-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-11-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-15-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(2-methylphenyl)-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-16-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



RN 787633-17-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(2-amino-4-chlorophenyl)methyl]-7-bromo-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



RN 787633-20-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-fluorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-21-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-hydroxyphenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787633-23-2 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-1-[4-(dimethylamino)butyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)



RN 787633-24-3 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)



RN 787633-25-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-methyl-1-piperazinyl)butyl]- (9CI) (CA INDEX NAME)



RN 787633-26-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-

chlorophenyl)-1-[3-(dimethylamino)propyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)



RN 787633-27-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787633-28-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-hydroxyphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-29-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-30-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787633-33-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 787633-34-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 787633-35-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-36-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-(1-propynyl)-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-37-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-38-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-40-3 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-methyl- (9CI) (CA INDEX NAME)



RN 787633-43-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-44-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-45-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-6-chloro-3-pyridinyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-48-1 CAPLUS
CN Piperazine, 1-[[(3S)-4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-

chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 787633-49-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-50-5 CAPLUS
CN Morpholine, 4-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-51-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-52-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-53-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **787633-93-6 787633-94-7 787633-98-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)

RN 787633-93-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-94-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-98-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **787633-63-0P 787633-64-1P 787633-71-0P**
787633-83-4P 787633-84-5P 787633-85-6P
787633-95-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)

RN 787633-63-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-64-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-71-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-83-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-84-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-85-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-bromo-4-[(4-chloro-2-nitrophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-,

1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-95-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **791613-68-8P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted 1,4-diazepines as inhibitors of HDM2-p53 interactions)
RN 791613-68-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Appl's

L5 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:934324 CAPLUS Full-text
DN 141:395589
TI Preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease.
IN Lu, Tianbao; Milkiewicz, Karen L.; Raboisson, Pierre; Cummings, Maxwell David; Calvo, Raul R.; Parks, Daniel J.; Lafrance, Louis V.; Marugan, Sanchez Juan Jose; Gushue, Joan; Leonard, Kristi
PA USA
SO U.S. Pat. Appl. Publ., 58 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004220179	A1	20041104	US 2004-829040	20040421
	US 2005227932	A1	20051013	US 2005-72391	20050304
PRAI	US 2003-465264P	P	20030425		
	US 2002-292876	A2	20021113		
	US 2004-829040	A1	20040421		

OS MARPAT 141:395589
GI



I

AB Title compds. e.g. [I; Ra = halo, alkyl, alkenyl, alkynyl, cyano, cycloalkyl, OH, alkoxy, CO2H, alkoxycarbonyl, acyl, carbamoyl, (alkyl)aminocarbonyl, alkylthio, amino, NO2; X = alkylene, cycloalkylene, (substituted) arylene, heteroarylene, arylalkylene, heteroarylalkylene; R3 = CO2Rd, CO2M; Rd = H, alkyl, (substituted) cycloalkyl; M = cation; R5, R6 = (substituted) cycloalkyl, aryl, heteroaryl, cycloalkylalkyl, aralkyl, heteroarylalkyl, (unsatd.) heterocyclyl; R7 = H, alkyl, cycloalkyl, cycloalkylalkyl; R8 = H, alkyl; n = 0-2], were prepared Thus, 4-[(R)-1-(2-amino-4-chlorophenyl)ethyl]-(3S)-3-(4-chlorophenyl)-7-iodo-1- [2-(2-methoxyethoxy)ethyl]-1,4-benzodiazepine-2,5-dione inhibited MDM2 binding to a p53 peptide analog with IC50 = 0.1-1.0 μM.

IT **787632-60-4P**, 4-[1-(2-Amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-7-iodo-1-[2-(4-morpholino)ethyl]-1,4-benzodiazepine-2,5-dione **787632-61-5P 787632-62-6P 787632-64-8P 787632-65-9P 787632-66-0P 787632-67-1P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)

RN 787632-60-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787632-61-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 787632-62-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 787632-64-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-65-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-66-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-67-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



IT **528849-68-5P 787632-68-2P 787632-69-3P**
787632-70-6P 787632-71-7P 787632-72-8P
787632-73-9P 787632-74-0P 787632-75-1P
787632-76-2P 787632-77-3P 787632-78-4P
787632-79-5P 787632-80-8P 787632-81-9P
787632-82-0P 787632-83-1P 787632-84-2P
787632-85-3P 787632-86-4P 787632-87-5P
787632-88-6P 787632-89-7P 787632-98-8P
787632-99-9P 787633-00-5P 787633-01-6P
787633-02-7P 787633-03-8P 787633-04-9P
787633-05-0P 787633-06-1P 787633-07-2P
787633-08-3P 787633-09-4P 787633-10-7P
787633-11-8P 787633-15-2P 787633-16-3P
787633-17-4P 787633-20-9P 787633-21-0P
787633-23-2P 787633-24-3P 787633-25-4P
787633-26-5P 787633-27-6P 787633-28-7P
787633-29-8P 787633-30-1P 787633-33-4P
787633-34-5P 787633-35-6P 787633-36-7P
787633-37-8P 787633-38-9P 787633-40-3P
787633-43-6P 787633-44-7P 787633-45-8P
787633-48-1P 787633-49-2P 787633-50-5P
787633-51-6P 787633-52-7P 787633-53-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)

RN 528849-68-5 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-68-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-69-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethyl)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-70-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-3-[4-(trifluoromethoxy)phenyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-71-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-hexanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-72-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-heptanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-73-9 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-74-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-butanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA

INDEX NAME)

Absolute stereochemistry.



RN 787632-75-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-propanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-76-2 CAPLUS
CN 2-Furancarboxylic acid, 5-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-77-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 8-chloro-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)-

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-78-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)cyclopropylmethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-79-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(3,4-dichlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-80-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(3-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-81-9 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-3-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-82-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-4-[1-(4-methyl-1-naphthalenyl)ethyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-83-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(4-chlorophenyl)methyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-84-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[2-(4-chlorophenyl)-1-methylethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787632-85-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-bromophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-86-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-acetic acid, 3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 787632-87-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-3-nitrophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-88-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-89-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(3-amino-4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-98-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methoxycarbonyl)-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787632-99-9 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-carboxy-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, α-(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-00-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-(aminocarbonyl)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-01-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 787633-02-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-03-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-04-9 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-05-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-06-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-07-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-08-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(methylthio)-2,5-dioxo-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-09-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-[(trifluoromethyl)thio]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-10-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-11-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-15-2 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(2-methylphenyl)-2,5-dioxo-,

sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-16-3 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



RN 787633-17-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(2-amino-4-chlorophenyl)methyl]-7-bromo-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-, monosodium salt (9CI) (CA INDEX NAME)



RN 787633-20-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-

fluorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-21-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1R)-1-(2-amino-4-chloro-5-hydroxyphenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 787633-23-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-1-[4-(dimethylamino)butyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)



RN 787633-24-3 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-morpholinyl)butyl]- (9CI) (CA INDEX NAME)



RN 787633-25-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[4-(4-methyl-1-piperazinyl)butyl]- (9CI) (CA INDEX NAME)



RN 787633-26-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-1-[3-(dimethylamino)propyl]-3,4-dihydro-7-iodo- (9CI) (CA INDEX NAME)



RN 787633-27-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-morpholinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787633-28-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-hydroxyphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-29-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-30-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-4-chlorophenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[3-(4-methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)



RN 787633-33-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 787633-34-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 7-bromo-3-(4-chlorophenyl)-3,4-dihydro-1-methyl-4-(1-phenylethyl)- (9CI) (CA INDEX NAME)



RN 787633-35-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-36-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-7-(1-propynyl)-, sodium salt, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-37-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-38-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(1S)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-40-3 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-methyl- (9CI) (CA INDEX NAME)



RN 787633-43-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(2-methoxyethoxy)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



RN 787633-44-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-3,4-dihydro-1-[2-(4-morpholinyl)ethyl]-7-(1-propynyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-45-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(2-amino-6-chloro-3-pyridinyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 787633-48-1 CAPLUS
CN Piperazine, 1-[[(3S)-4-[(1R)-1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 787633-49-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[(4-chloro-2-methylphenyl)methyl]-3-(4-chlorophenyl)-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 787633-50-5 CAPLUS
CN Morpholine, 4-[[(3S)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-1H-1,4-benzodiazepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-51-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-52-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(4-morpholinyl)ethyl]-, (3R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-53-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-3,4-dihydro-7-iodo-1-[2-(2-methoxyethoxy)ethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **787633-93-6 787633-94-7 787633-95-8 787633-98-1**
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)
RN 787633-93-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-acetyl-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-94-7 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-95-8 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-7-ethynyl-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-98-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[(1R)-1-(4-chlorophenyl)ethyl]-3-[4-chloro-2-(2-propenyloxy)phenyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **787633-63-0P 787633-64-1P 787633-71-0P**
787633-83-4P 787633-84-5P 787633-85-6P
787634-02-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzodiazepinediones as inhibitors of HDM2-p53 interactions for treatment of cancer and autoimmune disease)

RN 787633-63-0 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-64-1 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-(1-hydroxyethyl)-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-71-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chloro-2-hydroxyphenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 787633-83-4 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(4-chloro-2-nitrophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-84-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[1-(2-amino-4-chlorophenyl)ethyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787633-85-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-bromo-4-[(4-chloro-2-nitrophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 787634-02-0 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 7-(aminocarbonyl)-3-(4-chlorophenyl)-4-[(1R)-1-(4-chlorophenyl)ethyl]-2,3,4,5-tetrahydro-2,5-dioxo-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:913286 CAPLUS Full-text
DN 140:776
TI Method using benzodiazepine compounds for cytoprotection through MDM2 and HDM2 inhibition
IN Koblish, Holly K.; Manthey, Carl L.; Molloy, Christopher J.; Lu, Tianbao; Parks, Daniel J.; Lafrance, Luis V., III; Milkiewicz, Karen L.; Carver, Ted; Grasberger, Bruce L.
PA 3-Dimensional Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003095625	A2	20031120	WO 2003-US14923	20030513
WO 2003095625	A3	20040715		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-379617P P 20020513
OS MARPAT 140:776
AB The invention provides a method for protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class of 1,4-benzodiazepines which act as inhibitors of MDM2-p53 interactions. The method of the invention can be employed as an adjunct to chemotherapy or radiation therapy. In addition, the methods of the invention can be employed to treat a disease or condition that involves excessive cell death.
IT **528848-14-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)(benzodiazepine compds. for cytoprotection through MDM2 and HDM2 inhibition)
RN 528848-14-8 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[(4-methylphenyl)methyl]-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)


Ph
HO2C—CH
O
N
I
Cl
N
O
CH2
Me

L5 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:396722 CAPLUS Full-text
DN 138:401764
TI Preparation of substituted 1,4-benzodiazepinediones as MDM2 oncoprotein inhibitors for the treatment of cancer
IN Lu, Tianbao; Lafrance, Louis V., III; Parks, Daniel J.; Milkiewicz, Karen L.; Calvo, Raul R.; Cummings, Maxwell David; Kim, Alexander J.; Grasberger, Bruce L.; Carver, Theodore E., Jr.
PA 3-Dimensional Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 139 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003041715	A1	20030522	WO 2002-US36208	20021113
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2466055	AA	20030522	CA 2002-2466055	20021113
	US 2003109518	A1	20030612	US 2002-292876	20021113
	EP 1443937	A1	20040811	EP 2002-778828	20021113
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2002014048	A	20041013	BR 2002-14048	20021113
	JP 2005509005	T2	20050407	JP 2003-543602	20021113
	ZA 2004003082	A	20050422	ZA 2004-3082	20040422
	NO 2004002146	A	20040811	NO 2004-2146	20040525
PRAI	US 2001-331235P	P	20011113		
	WO 2002-US36208	W	20021113		

OS MARPAT 138:401764
GI



I



II

AB Title compds. I [wherein X and Y = independently CO, CH2, or CS; R1-R4 = independently H, halo, (cyclo)alkyl, alkenyl, alkynyl, alkoxy(carbonyl), CN, NH2, alkanoylamino, NO2, OH, CO2H, and (un)substituted (hetero)aryl, (hetero)aralkyl, or (hetero)aryloxy; or R1R2, R2R3, or R3R4 = (CH2)u, CH=CHCH=CH, or CH2CH=CHCH2; u = 3-6; R5 = H, (cyclo)alkyl, carboxyalkyl, alkoxycarbonyl(alkyl), (alkyl)aminocarbonyl(alkyl), or (un)substituted (hetero)aryl or (hetero)aralkyl; R6 and R9 = independently (un)substituted cycloalkyl(alkyl), (hetero)aryl, (hetero)aralkyl, or heterocyclyl; R7 and R8 = independently H or alkyl; R10 = (CH2)nCO2Rb, (CH2)mCO2M, (CH2)iOH, or (CH2)jCONRcRd; Rb = H, alkyl, or (un)substituted cycloalkyl or heterocyclyl; M

= a cation; Rc and Rd = independently H or (un)substituted (cyclo)alkyl, (hetero)alkyl, (hetero)aralkyl, or heterocyclyl; n = 0-8; m = 0-8; i = 1-8; j = 0-8; and solvates, hydrates, and pharmaceutically acceptable salts thereof] were prepared as inhibitors of HDM2-p53 interactions. Examples include general synthetic procedures and phys. data for 216 invention compds., as well as exptl. details and results from a fluorescent peptide assay. For instance, the benzodiazepinedione II, which was prepared starting from an anthranilic acid derivative, inhibited the binding of a p53 peptide analog to MDM2 residues 17-125 with an IC50 value of 1.7 μM. Thus, I are useful for the prevention or treatment of a variety of cancers, inflammatory conditions, and autoimmune diseases (no data).

IT **528848-05-7P**, [1-Benzyl-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-06-8P**, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-phenethyl-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-07-9P**, [3-(4-Chlorophenyl)-7-iodo-1-isobutyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-08-0P**, [3-(4-Chlorophenyl)-7-iodo-1-(3-methylbutyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-09-1P**, [3-(4-Chlorophenyl)-1-cyclobutylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-10-4P**, [3-(4-Chlorophenyl)-1-cyclopentylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-11-5P**, [3-(4-Chlorophenyl)-1-cyclohexylmethyl-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-12-6P**, [3-(4-Chlorophenyl)-7-iodo-1-(2-methylbenzyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-13-7P**, [3-(4-Chlorophenyl)-7-iodo-1-(3-methylbenzyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-14-8P**, [3-(4-Chlorophenyl)-7-iodo-1-(4-methylbenzyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-15-9P**, [3-(4-Chlorophenyl)-7-iodo-1-(naphthalen-2-yl)methyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-16-0P**, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(pyridin-2-ylmethyl)-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-17-1P**, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(pyridin-3-ylmethyl)-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-18-2P**, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(pyridin-4-ylmethyl)-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-21-7P**, [3-(4-Chlorophenyl)-7-iodo-1-methyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528848-22-8P**, [3-(4-Chlorophenyl)-7-iodo-2,5-dioxo-1-(3-phenylpropyl)-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]phenylacetic acid **528849-41-4P**, 3-[4-[(Carboxy)(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-2,3,4,5-tetrahydrobenzo[e][1,4]diazepin-1-yl]propionic acid **528849-43-6P**, [1-(2-tert-Butoxycarbonylaminoethyl)-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl](4-chlorophenyl)acetic acid **528849-45-8P**, (4-Chlorophenyl)[3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1-[2-(pyridin-2-yl)ethyl]-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid **528849-46-9P**, (4-Chlorophenyl)[3-(4-chlorophenyl)-7-iodo-1-(methylcarbamoylmethyl)-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid **528849-49-2P**, (4-Chlorophenyl)[3-(4-chlorophenyl)-7-iodo-1-methyl-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid **528849-51-6P**, [1-Carboxymethyl-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl](4-chlorophenyl)acetic acid methyl ester **528849-53-8P**, (4-Chlorophenyl)[3-(4-chlorophenyl)-1-((R)-2,3-dihydroxypropyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid **528849-66-3P**,

(4-Chlorophenyl)[3-(4-chlorophenyl)-1-((S)-2,3-dihydroxypropyl)-7-iodo-2,5-dioxo-1,2,3,5-tetrahydrobenzo[e][1,4]diazepin-4-yl]acetic acid **528849-67-4P**, 5-[4-[(Carboxy)(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-2,3,4,5-tetrahydrobenzo[e][1,4]diazepin-1-yl]pentanoic acid **528849-68-5P**, 5-[3-(4-Chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-7-iodo-2,5-dioxo-2,3,4,5-tetrahydrobenzo[e][1,4]diazepin-1-yl]pentanoic acid **528849-69-6P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anticancer agent; preparation of benzodiazepinediones as p53 MDM2 binding inhibitors for treatment of cancer, inflammatory conditions, and autoimmune diseases)

RN 528848-05-7 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 528848-06-8 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl-1-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 528848-07-9 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-(2-methylpropyl)-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-08-0 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-(3-methylbutyl)-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-09-1 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1-(cyclobutylmethyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-10-4 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1-(cyclopentylmethyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-11-5 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1-

(cyclohexylmethyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-12-6 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[(2-methylphenyl)methyl]-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-13-7 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[(3-methylphenyl)methyl]-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-14-8 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[(4-methylphenyl)methyl]-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-15-9 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-(2-naphthalenylmethyl)-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-16-0 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl-1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 528848-17-1 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl-1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 528848-18-2 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl-1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 528848-21-7 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-methyl-2,5-dioxo-α-phenyl- (9CI) (CA INDEX NAME)



RN 528848-22-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, 3-(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-α-phenyl-1-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 528849-41-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-propanoic acid, 4-[carboxy(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-43-6 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, α,3-bis(4-chlorophenyl)-1-[2-[[(1,1-dimethylethoxy)carbonyl]amino]ethyl]-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-45-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, α,3-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo-1-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 528849-46-9 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, α,3-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-[2-(methylamino)-2-oxoethyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-49-2 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, α,3-bis(4-chlorophenyl)-1,2,3,5-tetrahydro-7-iodo-1-methyl-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-51-6 CAPLUS

CN 1H-1,4-Benzodiazepine-1,4(5H)-diacetic acid, α4,3-bis(4-chlorophenyl)-2,3-dihydro-7-iodo-2,5-dioxo-, 4-methyl ester (9CI) (CA INDEX NAME)



RN 528849-53-8 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, α,3-bis(4-chlorophenyl)-1-[(2R)-2,3-dihydroxypropyl]-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528849-66-3 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetic acid, α,3-bis(4-chlorophenyl)-1-[(2S)-2,3-dihydroxypropyl]-1,2,3,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528849-67-4 CAPLUS

CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 4-[carboxy(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-68-5 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-hydroxyethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 528849-69-6 CAPLUS
CN 1H-1,4-Benzodiazepine-1-pentanoic acid, 3-(4-chlorophenyl)-4-[1-(4-chlorophenyl)-2-(diethylamino)-2-oxoethyl]-2,3,4,5-tetrahydro-7-iodo-2,5-dioxo- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:320256 CAPLUS Full-text
DN 140:77117
TI Diastereoselective alkylation of a chiral 1,4-benzodiazepine-2,5-dione containing the α-phenethyl group. Attempted asymmetric synthesis of α,β-diaminopropionic acid
AU Becerril, Amayaly; Leon-Romo, Jose Luis; Avina, Judit; Castellanos, Elena; Juaristi, Eusebio
CS Departmento de Quimica, Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional, Mexico, D.F., 07000, Mex.
SO ARKIVOC (Gainesville, FL, United States) (2002), (12), 4-14
CODEN: AGFUAR
URL: http://www.arkat-usa.org/ark/journal/2002/Muchowski/JM-602F/602F.pdf
PB Arkat USA Inc.
DT Journal; (online computer file)
LA English
OS CASREACT 140:77117
GI



I



II

AB Alkylation of chiral benzodiazepinedione (S)-I with LDA or LHMDS with N-(bromomethyl)-phthalimide (a protected derivative of bromomethylamine), via the lithium enolate of (S)-I in the presence of HMPA as cosolvent was accomplished in moderate yield and good diastereoselectivity. Hydrolysis of the resultant major diastereomeric product (S,R)-II with 57% HI afforded the desired α,β-aminopropionic acid in good yield albeit in racemic form, probably due to β-elimination-addition of ammonia under these conditions.
IT **641630-70-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(base promoted diastereoselective alkylation of chiral N-methyl-N'-phenethylbenzodiazepinedione)
RN 641630-70-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3,4-dihydro-1-methyl-4-[(1S)-1-phenylethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT **641630-71-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(base promoted diastereoselective alkylation of chiral N-methyl-N'-phenethylbenzodiazepinedione)
RN 641630-71-9 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-3,4-dihydro-1-methyl-4-[(1S)-1-phenylethyl]-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:242698 CAPLUS Full-text
DN 138:385412
TI Solid-Phase Synthesis of 7-Acylamino-1,4-benzodiazepine-2,5-diones
AU Ettmayer, Peter; Chloupek, Stefan; Weigand, Klaus
CS Novartis Forschungsinstitut, Vienna, A-1235, Austria
SO Journal of Combinatorial Chemistry (2003), 5(3), 253-259
CODEN: JCCHFF; ISSN: 1520-4766
PB American Chemical Society
DT Journal
LA English
OS CASREACT 138:385412
AB A method for the synthesis of polymer-bound 7-acylamino-benzodiazepine-2,5-diones is described. The amino group of an α-amino acid is linked to polystyrene or TentaGel resin via reductive amination of polymer-bound 4-alkoxy-2,6-dimethoxybenzaldehyde. Acylation with unprotected 5-nitroanthranilic acid is followed by base-catalyzed ring closure. Reduction of the nitro group yields enantiomerically pure 7-aminobenzodiazepin-2,5-dione attached via the N-4 atom to the resin. Acylation of the amino group on the aromatic ring with acid chlorides in N-methylpyrrolidone (no DMF, no base) followed by cleavage from the resin using TFA/Me2S/water (90:5:5) provides the acylated benzodiazepinones in 52-69% (PS resin) and 41-48% (TG resin) yield (based on the theor. loading) and >70% purity (HPLC, 210 nm). Using Fmoc-protected tyrosine fluoride in NMP gives the amino acid-coupled benzodiazepinones in 24% (PS resin) and 31% (TG resin) yield.
IT **528603-50-1DP**, polymer-supported **528603-52-3DP**, polymer-supported
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(solid-phase synthesis of 7-acylamino-1,4-benzodiazepine-2,5-diones)
RN 528603-50-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-(cyclohexylmethyl)-3,4-dihydro-4-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]-1-methyl-7-nitro-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 528603-52-3 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 7-amino-3-(cyclohexylmethyl)-3,4-dihydro-4-[(4-hydroxy-2,6-dimethoxyphenyl)methyl]-1-methyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:172564 CAPLUS Full-text
DN 136:355222
TI A New Resin-Bound Universal Isonitrile for the Ugi 4CC Reaction: Preparation and Applications to the Synthesis of 2,5-Diketopiperazines and 1,4-Benzodiazepine-2,5-diones
AU Kennedy, April L.; Fryer, Andrew M.; Josey, John A.
CS Array BioPharma, Boulder, CO, 80301, USA
SO Organic Letters (2002), 4(7), 1167-1170
CODEN: ORLEF7; ISSN: 1523-7060
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:355222
AB The preparation and synthetic applications of a novel resin-bound isonitrile are described. The resin is an example of a novel convertible isonitrile that can be utilized in the Ugi multicomponent reaction. Base-activation of the resin-bound Ugi product results in cleavage via formation of a N-acyloxazolidone that is then trapped as a carboxylic acid ester. This resin and the methodol. described are suitable for synthesizing diversity libraries of 2,5-diketopiperazines and 1,4-benzodiazepine-2,5-diones.
IT **422309-10-2P 422309-12-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2,5-diketopiperazine and 1,4-benzodiazepine-2,5-dione libraries via Ugi four-component condensation with polymer-supported isocyanide)
RN 422309-10-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[2-(4-chlorophenyl)ethyl]-3-cyclohexyl-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)





RN 422309-12-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-cyclohexyl-3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)





RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2001:115088 CAPLUS Full-text
DN 134:178141
TI Preparation of oxoazacycloalkanes and analogs
IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrissette, Mathew M.; Ma, Liang; Cherrier, Marie-Pierre
PA Aventis Pharmaceuticals Products, Inc., USA
SO PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001010799	A1	20010215	WO 2000-US21257	20000803
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6492553	B1	20021210	US 1999-368213	19990804
	EP 1212269	A1	20020612	EP 2000-955355	20000803
	EP 1212269	B1	20041027		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, MC, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506420	T2	20030218	JP 2001-515272	20000803
	AT 280744	E	20041115	AT 2000-955355	20000803
	ES 2230143	T3	20050501	ES 2000-955355	20000803
	HK 1046897	A1	20050415	HK 2002-108269	20021115
PRAI	US 1999-368213	A	19990804		
	US 1998-73007P	P	19980129		
	US 1998-98404P	P	19980831		
	US 1998-98708P	P	19980901		
	US 1998-101056P	P	19980918		
	WO 1999-US1923	A2	19990129		
	WO 2000-US21257	W	20000803		

OS CASREACT 134:178141; MARPAT 134:178141
GI



I

AB The title process comprises, e.g., Ugi condensation of N-protected anthranilic acids, amines, aldehydes, and an isocyanide followed by deprotection and cyclization. Thus, 2-(BocMeN)C6H4CO2H, imidazole-1-propanamine, PhCH2CH2CHO, and an isocyanide were combined to give title compound I.
IT **214854-07-6P 325954-59-4P 325954-60-7P**
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)(preparation of oxoazacycloalkanes and analogs)
RN 214854-07-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 325954-59-4 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetamide, N-butyl-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-α-(2-phenylethyl)-3-(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 325954-60-7 CAPLUS

CN 4H-1,4-Benzodiazepine-4-acetamide, 1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-α-phenyl-N,3-bis(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:495272 CAPLUS Full-text
DN 131:130011
TI Preparation of N-acyl-2-aminoacetamides and cyclization products thereof.
IN Hulme, Christopher; Morton, George C.; Salvino, Joseph M.; Labaudiniere, Richard F.; Mason, Helen J.; Morrissette, Matthew M.; Ma, Liang; Cherrier, Marie-Pierre
PA Rhone-Poulenc Rorer Pharmaceuticals Inc., USA
SO PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9938844	A1	19990805	WO 1999-US1923	19990129
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2318601	AA	19990805	CA 1999-2318601	19990129
	AU 9924821	A1	19990816	AU 1999-24821	19990129
	AU 747987	B2	20020530		
	ZA 9900729	A	20000110	ZA 1999-729	19990129
	EP 1051397	A1	20001115	EP 1999-904421	19990129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO				
	BR 9908207	A	20001128	BR 1999-8207	19990129
	JP 2002501944	T2	20020122	JP 2000-530081	19990129
	US 6492553	B1	20021210	US 1999-368213	19990804
	NO 2000003792	A	20000927	NO 2000-3792	20000724
	BG 104724	A	20010330	BG 2000-104724	20000829
PRAI	US 1998-73007P	A2	19980129		
	US 1998-98404P	A2	19980831		
	US 1998-98708P	A2	19980901		
	US 1998-101056P	A2	19980918		
	WO 1999-US1923	W	19990129		

OS MARPAT 131:130011
AB RaRbNCRcaRcbRd Ra = RaaCO; Dd = CONHRda; Raa, Rb, Rca, Rcb = H, (substituted) aliphatyl, aryl; Rda = (substituted) aliphatyl, aryl; with provisos were prepared by reaction of RcaCORcb with RbNH2, RaCO2H, and NCRda. Title compds. may be prepared on a isocyanide resin and deprotected/cyclized to give 1,4-benzodiazepine-2,5-diones, diketopiperazines, ketopiperazines, lactams, 1,4-benzodiazapines, and dihydroquinoxalinones.
IT **214854-07-6P 234781-74-9P 234781-75-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of N-acyl-2-aminoacetamides and cyclization products thereof)
RN 214854-07-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 234781-74-9 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetamide, N-butyl-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-α-(2-phenylethyl)-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 234781-75-0 CAPLUS
CN 4H-1,4-Benzodiazepine-4-acetamide, 1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-α-phenyl-N,3-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:197527 CAPLUS Full-text
DN 130:325356
TI Enantioselective Synthesis of α-Amino Acids from Chiral 1,4-Benzodiazepine-2,5-diones Containing the α-Phenethyl Group
AU Juaristi, Eusebio; Leon-Romo, Jose Luis; Ramirez-Quiros, Yara
CS Departamento de Quimica Centro de Investigacion y de Estudios Avanzados, Instituto Politecnico Nacional, Mexico City, 07000, Mex.
SO Journal of Organic Chemistry (1999), 64(8), 2914-2918
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 130:325356
GI



I

AB Chiral benzodiazepinedione (S)-I was prepared in good yield from N-methylisatoic anhydride and (S)-a-phenylethylamine. Enolate (S)-I-Li was alkylated in high yield and with good diastereoselectivity with various electrophiles and in the presence of HMPA as cosolvent. Hydrolysis of the main products with 57% HI proceeded in excellent yield to afford enantiopure a-substituted a-amino acids.

IT **223755-94-0P**
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(enantioselective synthesis of α-amino acids from chiral benzodiazepinediones containing the α-phenethyl group)

RN 223755-94-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-4-[(1S)-1-phenylethyl]-3-(phenylmethyl)-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:632419 CAPLUS Full-text
DN 130:3837
TI Improved Procedure for the Solution Phase Preparation of 1,4-Benzodiazepine-2,5-dione Libraries via Armstrong's Convertible Isonitrile and the Ugi Reaction
AU Hulme, Christopher; Peng, John; Tang, Sheng-Yuh; Burns, Christopher J.; Morize, Isabelle; Labaudiniere, Richard
CS Lead Discovery Department, Rhone-Poulenc Rorer Central Research, Collegeville, PA, 19426-0995, USA
SO Journal of Organic Chemistry (1998), 63(22), 8021-8023
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
GI



I



II

AB Title compds. I (R1 = (CH3)2CH, CH3(CH2)5, C6H5CH2CH2, CH3CH2, etc.; R2 = C6H5CH2, C6H5CH2CH2, C6H5(CH2)3, 4-MeOC6H4CH2, CH3(CH2)5, etc.; R3 = H, CH3) were prepared from R1CHO, R2NH2, 1-cyclohexenylisonitrile, and II by 4-component condensation in methanol at room temperature
IT **214854-07-6P 215650-70-7P 215650-73-0P**
215650-74-1P 215650-75-2P 215650-86-5P
215650-89-8P 215650-90-1P 215650-91-2P
215651-02-8P 215651-05-1P 215651-06-2P
215651-07-3P 215651-17-5P 215651-20-0P
215651-21-1P 215651-22-2P 215651-65-3P
215651-66-4P 215651-77-7P 215651-80-2P
215651-81-3P 215651-82-4P 215651-93-7P
215651-96-0P 215651-97-1P 215651-98-2P
215652-07-6P 215652-09-8P 215652-10-1P
215652-21-4P 215652-24-7P 215652-25-8P
215652-26-9P 215652-37-2P 215652-40-7P
215652-41-8P 215652-42-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(procedure for solution phase preparation of benzodiazepinedione libraries via
Armstrong's convertible isonitrile and Ugi reaction)
RN 214854-07-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215650-70-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(2-phenylethyl)-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 215650-73-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 215650-74-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 215650-75-2 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(phenylmethyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX

NAME)



RN 215650-86-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3,4-bis(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215650-89-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215650-90-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215650-91-2 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(2-phenylethyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-02-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(2-phenylethyl)-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 215651-05-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 215651-06-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 215651-07-3 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(3-phenylpropyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-17-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[(4-methoxyphenyl)methyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215651-20-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-4-[(4-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 215651-21-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-4-[(4-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 215651-22-2 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-4-[(4-methoxyphenyl)methyl]-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-65-3 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 215651-66-4 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-77-7 CAPLUS
CN Benzenesulfonamide, 4-[2-[1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-3-(2-phenylethyl)-4H-1,4-benzodiazepin-4-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 215651-80-2 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-4H-1,4-benzodiazepin-4-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 215651-81-3 CAPLUS
CN Benzenesulfonamide, 4-[2-[3-[(3,3-dimethylcyclohexyl)methyl]-1,2,3,5-tetrahydro-1-methyl-2,5-dioxo-4H-1,4-benzodiazepin-4-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 215651-82-4 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[4-[2-[4-(aminosulfonyl)phenyl]ethyl]-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215651-93-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215651-96-0 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 215651-97-1 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-4-[[4-(1,1-dimethylethyl)phenyl]methyl]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 215651-98-2 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[4-[[4-(1,1-dimethylethyl)phenyl]methyl]-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215652-07-6 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(2-phenylethyl)-4-(5-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 215652-09-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-(5-quinolinylmethyl)- (9CI) (CA INDEX NAME)



RN 215652-10-1 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-(5-quinolinylmethyl)-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215652-21-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 4-(2,2-diphenylethyl)-3,4-dihydro-1-

methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215652-24-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-4-(2,2-diphenylethyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 215652-25-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-4-(2,2-diphenylethyl)-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 215652-26-9 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[4-(2,2-diphenylethyl)-2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 215652-37-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-4-[3-(2-oxo-1-pyrrolidinyl)propyl]-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 215652-40-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[2-(1,3-benzodioxol-5-yl)-1-methylethyl]-3,4-dihydro-1-methyl-4-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 215652-41-8 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[(3,3-dimethylcyclohexyl)methyl]-3,4-dihydro-1-methyl-4-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 215652-42-9 CAPLUS
CN Cyclopropanecarboxylic acid, 2-[2,3,4,5-tetrahydro-1-methyl-2,5-dioxo-4-[3-(2-oxo-1-pyrrolidinyl)propyl]-1H-1,4-benzodiazepin-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)



IT **215651-64-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(solution phase preparation of benzodiazepinediones via Armstrong's convertible
isonitrile and Ugi reaction)
RN 215651-64-2 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[1-(1,3-benzodioxol-5-yl)ethyl]-3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:624893 CAPLUS Full-text
DN 129:316200
TI Novel safety-catch linker and its application with a Ugi/De-BOC/cyclization (UDC) strategy to access carboxylic acids, 1,4-benzodiazepines, diketopiperazines, ketopiperazines and dihydroquinoxalinones
AU Hulme, Christopher; Peng, John; Morton, George; Salvino, Joseph M.; Herpin, Tim; Labaudiniere, Richard
CS Rhone-Poulenc Rorer Cent. Res., Collegeville, PA, 19426, USA
SO Tetrahedron Letters (1998), 39(40), 7227-7230
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
GI



I





II



III



IV



V

AB This communication reveals the synthesis and application of a novel resin bound isonitrile (I; A1 = isocyano; P = Wang resin) which can be used for automated parallel synthesis of diverse arrays of compds. in combinatorial chemical The resin is an example of a novel safety-catch linker which upon BOC-activation can be resin cleaved with a variety of nucleophiles. Use of this polymer supported isonitrile in the Ugi multi-component reaction (MCR) with aldehydes R1CHO (R1 = unspecified aldehyde residue), amines R2NH2 (R2 = unspecified amine residue), and carboxylic acids R3CO2H (R3 = unspecified carboxylic acid residue) to form resin-bound Ugi products I (A1 = Q, R = H) followed by Boc-activation to I (A1 = Q, R = Boc) (i.e. safety catch) and resin clipping and cyclization. allows access to diverse arrays of 1,4-benzodiazepine-2,5-diones (II; R4 = unspecified substituent), diketopiperazines (III), ketopiperazines (IV), and dihydroquinoxalines (V), resp., as well as carboxylic acids (amino acids) (HO-Q) or their esters. The methoxide safety-catch clipping strategy and subsequent solution phase cyclization. offers similar advantages to a traceless linker.
IT **214854-07-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(safety-catch linker resin and its application with Ugi/De-BOC/cyclization strategy to access carboxylic acids, benzodiazepines, diketopiperazines, ketopiperazines and

dihydroquinoxalinones)

RN 214854-07-6 CAPLUS

CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-4-[3-(1H-imidazol-1-yl)propyl]-1-methyl-3-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1996:705648 CAPLUS Full-text
DN 126:31333
TI A Remarkable Two-Step Synthesis of Diverse 1,4-Benzodiazepine-2,5-diones Using the Ugi Four-Component Condensation
AU Keating, Thomas A.; Armstrong, Robert W.
CS Department of Chemistry and Biochemistry, University of California, Los Angeles, CA, 90095, USA
SO Journal of Organic Chemistry (1996), 61(25), 8935-8939
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
GI



I

AB A two-step, general synthesis of 1,4-benzodiazepine-2,5-diones was presented. This synthesis employed an Ugi four-component condensation using a convertible isocyanide (1-isocyanocyclohexene), followed by an acid-activated cyclization reaction. The condensation of 2-amino-5-iodobenzoic acid with 1-butanamine, benzaldehyde and 1-isocyanocyclohexene gave 4-butyl-3,4-dihydro-7-iodo-3-phenyl-1H-1,4- benzodiazepine-2,5-dione (I). This synthesis represented a dramatically improved route to 1,4-benzodiazepine-2,5-diones over those currently in the literature. In addition, since amino acids are not used as inputs, the potential for mol. diversity is much greater than that with existing syntheses. It was also found that 1,4-benzodiazepine-2,5-diones substituted with methylenes at the C-3 and N-4 positions display conformational isomerism in the NMR spectra at room temperature Variable-temperature NMR expts. support this observation and offer the interesting conclusion that the 1,4-benzodiazepine-2,5-dione core structure, in certain examples, might not be as rigid as previously supposed.

IT **184287-14-7P 184287-20-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of benzodiazepinediones by Ugi four-component condensation)

RN 184287-14-7 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-1-methyl-3-(4-methylphenyl)-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 184287-20-5 CAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3,4-dihydro-3-(4-methylphenyl)-1-phenyl-4-(2-phenylethyl)- (9CI) (CA INDEX NAME)



=> d l2; d his; log y
L2 HAS NO ANSWERS
L1 STR



G1 Cb,Hy,Ak

Structure attributes must be viewed using STN Express query preparation.
L2 QUE ABB=ON PLU=ON L1

(FILE 'HOME' ENTERED AT 12:20:46 ON 30 NOV 2005)

FILE 'REGISTRY' ENTERED AT 12:20:52 ON 30 NOV 2005
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 7 S L2
L4 174 S L2 FUL

FILE 'CAPLUS' ENTERED AT 12:21:18 ON 30 NOV 2005
L5 13 S L4

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	65.12	226.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.49	-9.49

STN INTERNATIONAL LOGOFF AT 12:22:27 ON 30 NOV 2005